KR20240141340A - 보툴리눔 독소 액체 제형 및 그 용도 - Google Patents

보툴리눔 독소 액체 제형 및 그 용도 Download PDF

Info

Publication number
KR20240141340A
KR20240141340A KR1020247030641A KR20247030641A KR20240141340A KR 20240141340 A KR20240141340 A KR 20240141340A KR 1020247030641 A KR1020247030641 A KR 1020247030641A KR 20247030641 A KR20247030641 A KR 20247030641A KR 20240141340 A KR20240141340 A KR 20240141340A
Authority
KR
South Korea
Prior art keywords
liquid formulation
chelating agent
serum albumin
botulinum toxin
human serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030641A
Other languages
English (en)
Korean (ko)
Inventor
칼-하인즈 에이젤
클라우스 핀크
해롤드 뷔. 테일러
클라우디아 야츠크
카티아 퀴바흐
Original Assignee
메르츠 파마 게엠베하 운트 코. 카가아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르츠 파마 게엠베하 운트 코. 카가아 filed Critical 메르츠 파마 게엠베하 운트 코. 카가아
Publication of KR20240141340A publication Critical patent/KR20240141340A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
KR1020247030641A 2022-02-15 2023-02-14 보툴리눔 독소 액체 제형 및 그 용도 Pending KR20240141340A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156843 2022-02-15
EP22156843.9 2022-02-15
EP22183172 2022-07-05
EP22183172.0 2022-07-05
PCT/EP2023/053647 WO2023156389A1 (en) 2022-02-15 2023-02-14 Liquid botulinum toxin formulation and use thereof

Publications (1)

Publication Number Publication Date
KR20240141340A true KR20240141340A (ko) 2024-09-26

Family

ID=85202119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030641A Pending KR20240141340A (ko) 2022-02-15 2023-02-14 보툴리눔 독소 액체 제형 및 그 용도

Country Status (13)

Country Link
US (1) US20250152682A1 (https=)
EP (1) EP4479023A1 (https=)
JP (1) JP2025504249A (https=)
KR (1) KR20240141340A (https=)
CN (1) CN119031902A (https=)
AR (1) AR128514A1 (https=)
AU (1) AU2023221507A1 (https=)
CA (1) CA3243238A1 (https=)
CO (1) CO2024010940A2 (https=)
IL (1) IL315004A (https=)
MX (1) MX2024009970A (https=)
TW (1) TW202348248A (https=)
WO (1) WO2023156389A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
JP2006045173A (ja) * 2004-08-09 2006-02-16 Hidetoshi Tsuchida 表面修飾血清アルブミン−金属ポルフィリン複合体、およびそれを含有する酸素輸液
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
CA2766649C (en) * 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
PL3463432T3 (pl) * 2016-05-27 2021-04-19 Ipsen Biopharm Limited Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną

Also Published As

Publication number Publication date
MX2024009970A (es) 2024-09-18
US20250152682A1 (en) 2025-05-15
AR128514A1 (es) 2024-05-15
TW202348248A (zh) 2023-12-16
CN119031902A (zh) 2024-11-26
JP2025504249A (ja) 2025-02-06
WO2023156389A1 (en) 2023-08-24
CA3243238A1 (en) 2023-08-24
EP4479023A1 (en) 2024-12-25
IL315004A (en) 2024-10-01
CO2024010940A2 (es) 2024-09-19
AU2023221507A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
JP5080902B2 (ja) ボツリヌス毒素医薬組成物
KR101997615B1 (ko) 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
KR20240141340A (ko) 보툴리눔 독소 액체 제형 및 그 용도
KR101314952B1 (ko) 비-단백질 안정화된 클로스트리디움계 독소 약제학적조성물
CN110312505B (zh) 包含肉毒杆菌毒素的稳定液体组合物
KR20240150786A (ko) 보툴리눔 독소의 액체 제형 및 그 용도
CN103211774A (zh) 一种注射用甲磺酸加贝酯组合物及其制备方法
HK40113170A (zh) 液体肉毒杆菌毒素制剂及其用途
KR20260052068A (ko) 보툴리눔 독소 액체 제형 및 그 용도
CN121693325A (zh) 液体肉毒杆菌毒素制剂及其用途
HK40116988A (zh) 液体肉毒杆菌毒素制剂及其用途
CN110314132B (zh) 一种门冬氨酸鸟氨酸注射液及其制备方法
HK40008419B (en) Stable liquid composition comprising botulinum toxin
HK40008419A (en) Stable liquid composition comprising botulinum toxin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application